The race to end Bristol Myers Squibb’s exclusivity on its megablockbuster cancer drug Opdivo (nivolumab) is beginning in earnest, with Amgen looking to kick off a Phase III trial next month for its potential biosimilar to the drug.
The randomized, double-blind trial aims to enroll 620 participants and evaluate the…
Click here to view original post
